Jazz Pharmaceuticals plc — FY 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are noted separately below. The company is an international biopharmaceutical business focused on sleep and hematology/oncology products. Its financial statements received an unqualified audit opinion, and the auditor reported effective internal control over financial reporting.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 | Change |
|---|---|---|---|
| Total revenue | $1.619 billion | $1.488 billion | +9% |
| Net product sales | $1.601 billion | $1.477 billion | +8% |
| Operating income | $528.8 million | $591.7 million | -11% |
| Net income | $487.8 million | $396.8 million | +23% |
| Diluted EPS | $7.96 | $6.41 | +24% |
| Cash flow from operations | $693.1 million | $592.4 million | +17% |
Product gross margin, excluding acquired-intangible amortization and impairment, was 93.1%, versus 92.9% in 2016. Operating margin was approximately 32.7%, down from 39.8%; higher R&D, SG&A, acquired in-process R&D and intangible amortization contributed to the decline. FY 2017 net income included a provisional $148.8 million tax benefit from U.S. tax reform; excluding that benefit, the effective tax rate was 22.9% (reported rate: negative 10.8%).
At year-end, cash, cash equivalents and investments totaled $601.0 million, working capital was $674.3 million, and the company had $1.25 billion available under its undrawn revolving facility. Debt principal was approximately $1.827 billion: $676.8 million of term loans and $1.15 billion of exchangeable notes. Balance-sheet debt carrying value was $1.581 billion after discounts and issuance costs. Operating cash flow was positive; investing cash outflow was $269.0 million and financing cash outflow was $409.1 million. The company repurchased $98.8 million of shares during the year.
Fourth-quarter revenue was $436.4 million versus $396.6 million in Q4 2016. Quarterly net income was $232.2 million versus $116.7 million, with the FY 2017 tax benefit contributing materially to the annual result; Q4-specific attribution is not clearly detailed in the supplied filing text.
Products and changes versus prior year
- Xyrem: $1.187 billion of sales, up 7%; approximately 74% of net product sales. Growth reflected higher average net selling prices, while volumes were broadly unchanged. Prescription fulfillment delays and payer mix affected growth.
- Erwinaze/Erwinase: $197.3 million, down 2%, primarily reflecting supply interruptions partly offset by price increases.
- Defitelio/defibrotide: $133.7 million, up 23%, supported by U.S. launch and higher sales volume outside the U.S.
- Vyxeos: $33.8 million following its U.S. launch in August 2017; no comparable 2016 sales.
- Prialt: $27.4 million, down 6%. Other product sales fell 27%, mainly due to generic competition for psychiatry products.
Key developments included FDA approval and U.S. launch of Vyxeos, an FDA NDA submission for solriamfetol, and an EMA marketing application for Vyxeos. R&D expense rose 22% to $198.4 million; acquired in-process R&D expense rose to $85.0 million, primarily from the $75.0 million ImmunoGen collaboration payment. SG&A increased 8% to $544.2 million.
Outlook, risks and contingencies
- Management expected 2018 net product sales to increase, principally from Xyrem, Vyxeos and Defitelio, partly offset by decreases in certain other products. No numerical revenue or earnings guidance is provided in the supplied text. R&D and SG&A were expected to rise; gross margin percentage was expected to remain broadly stable.
- Xyrem concentration and competition: Xyrem accounted for about three-quarters of product sales. Nine generic ANDAs had been filed; five litigations were settled with entry rights generally scheduled from 2023 or 2025, subject to acceleration triggers. Litigation with remaining filers and appeals of adverse PTAB decisions on REMS patent claims remained unresolved. Generic or competing oxybate products could materially reduce sales.
- Supply and manufacturing: Erwinaze relied on sole supplier PBL, which faced an FDA warning letter and major MHRA inspection findings; the company reported constrained capacity, limited inventory and early-2018 supply disruptions. Vyxeos also relied on a single-site supplier and had experienced manufacturing batch failures. Most products and APIs depended on single-source suppliers.
- Development and launch: Solriamfetol remained subject to FDA review and DEA scheduling before any U.S. launch. Vyxeos’ European application was under review. Clinical, regulatory, reimbursement, market-acceptance and supply outcomes remain uncertain.
- Government and legal matters: The company was cooperating with a U.S. Attorney’s Office investigation concerning support for charities assisting Medicare patients; outcomes could include penalties or settlement. A French transfer-pricing assessment proposed approximately $45.9 million in tax, interest and penalties; the company disputed it. Xyrem patent and settlement-related antitrust scrutiny also posed potential exposure.
- Other exposures: Debt covenants and variable-rate term borrowing constrain flexibility; a 100-basis-point rate change was estimated to affect 2018 interest expense by about $4 million. Pricing and reimbursement pressure, foreign exchange movements, tax-law changes, and impairment risk on substantial goodwill and intangible assets were additional risks.
Important facts for investors to verify
- Track Xyrem prescription trends, net pricing, payer deductions, operational fulfillment and any changes to generic entry timing or litigation outcomes.
- Confirm remediation progress at PBL and whether Erwinaze supply and inventory recover; monitor Vyxeos manufacturing reliability and commercial uptake.
- Check regulatory decisions and launch prerequisites for solriamfetol and Vyxeos in Europe, including DEA scheduling and reimbursement conditions.
- Separate recurring earnings and cash generation from the $148.8 million provisional tax benefit; verify the final tax accounting and the status of the French assessment and government investigation.
- Reconcile debt principal with balance-sheet carrying value, monitor covenant headroom, scheduled maturities and cash available after investment, repurchases and business-development spending.